G
Ghaith Abu-Zeinah
Researcher at Cornell University
Publications - 29
Citations - 369
Ghaith Abu-Zeinah is an academic researcher from Cornell University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 19 publications receiving 182 citations. Previous affiliations of Ghaith Abu-Zeinah include Memorial Sloan Kettering Cancer Center & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Somatic mutations and cell identity linked by Genotyping of Transcriptomes
Anna S. Nam,Kyu-Tae Kim,Ronan Chaligne,Franco Izzo,Chelston Ang,Justin Taylor,Robert M. Myers,Ghaith Abu-Zeinah,Ryan M. Brand,Nathaniel D. Omans,Alicia Alonso,Caroline Sheridan,Marisa Mariani,Xiaoguang Dai,Eoghan D. Harrington,Alessandro Pastore,Juan R. Cubillos-Ruiz,Wayne Tam,Ronald Hoffman,Raul Rabadan,Joseph M. Scandura,Omar Abdel-Wahab,Peter Smibert,Dan A. Landau +23 more
TL;DR: Genotyping of Transcriptomes (GoT) is developed, a method to integrate genotyping with high-throughput droplet-based single-cell RNA sequencing that reveals that the transcriptional output of somatic mutations in myeloproliferative neoplasms is dependent on the native cell identity.
Journal ArticleDOI
Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma
James J. Harding,Ghaith Abu-Zeinah,Joanne F. Chou,Dwight H. Owen,Michele Ly,Maeve A. Lowery,Maeve A. Lowery,Marinela Capanu,Richard Do,Richard Do,Nancy E. Kemeny,Nancy E. Kemeny,Eileen M. O'Reilly,Eileen M. O'Reilly,Leonard B. Saltz,Leonard B. Saltz,Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa +17 more
TL;DR: Patients with AJCC stage IV HCC and bone metastases that are clinically evident on routine radiography or on clinical examination at presentation are apt to develop frequent, morbid, and mortal SREs, whereas those without evident bone metastasis at present are unlikely to develop these complications.
Journal ArticleDOI
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival.
Ghaith Abu-Zeinah,Spencer Krichevsky,Tatiana Cruz,Gabriela Hoberman,Diana Jaber,Niamh Savage,Claudia Sosner,Ellen K. Ritchie,Joseph M. Scandura,Richard T. Silver +9 more
TL;DR: In this article, the authors compared the myelofibrosis-free survival (MFS) and overall survival (OS) with rIFNα to two other primary treatments, hydroxyurea (HU) and phlebotomy-only (PHL-O).
Journal ArticleDOI
Understanding Sideroblastic Anemia: An Overview of Genetics, Epidemiology, Pathophysiology and Current Therapeutic Options.
TL;DR: The management of anemia in MDS subtypes with ring sideroblasts remains unique and includes the recently approved erythroid maturation agent, Luspatercept.
Journal ArticleDOI
Trends and Disparities in Cardiovascular Mortality Among Survivors of Hodgkin Lymphoma
Sadeer G. Al-Kindi,Ghaith Abu-Zeinah,Chang H. Kim,Vittal Hejjaji,Basem M. William,Basem M. William,Paolo Caimi,Paolo Caimi,Guilherme H. Oliveira,Guilherme H. Oliveira +9 more
TL;DR: Despite an overall decrease in CVM in HL survivors over the last decades, older patients, black patients, and men, especially those who have advanced-stage disease at diagnosis, are at the highest risk of cardiovascular death.